Japan Biosimilars- Landscape Today Outlook Tomorrow

NAVI MUMBAI, India - Jan. 10, 2020 - PRLog -- Japan Biosimilars (https://www.bharatbook.com/marketreports/japan-biosimilars-landscape-today-outlook-tomorrow/1941707) - Landscape Today Outlook Tomorrow

Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP "biosame" by originator Kyowa Hakko Kirin through its subsidiary, co-promotion/marketing collaboration with local companies for the front-end skill sets (Ayumi, Kyowa Hakko Kirin, Teijin) and few skipped listing to better manage constant supply (Pfizer), a key requirement by MHLW, makes Japan a distinct market vs. US and EU. Less stringent regulatory environment vs. US for approval, increasing healthcare burden and strong foothold of the marketers have played key roles in this early uptake which is at par to one of the best generic small molecule penetration in Japan in a short time (Filgrastim BS-volume share~45% in two years, Lantus BS- ~9% in 2 months vs. Lipitor generics ~50% volume share).

Request a free sample copy of Japan Biosimilars Market Report @ https://www.bharatbook.com/marketreports/sample/reports/1941707

While analyzing the launched biosimilar penetration since 2009 in Japan, bolstering uptake of Enbrel, Rituxan, and Lantus biosimilar vs. very slow uptake of Remicade BS mainly been attributed with the use of biosimilars in DPC hospitals,product reimbursement under high cost medical care benefit system and front end presence of the local partner. Despite the string of recent biosimilars approvals, healthcare professionals still harbor concerns over the quality of biosimilars. MHLW's announcement to update a decade back biosimilars guideline by FY2020 to reduce cost of development as well as to increase confidence of physician on quality, is indicative of biosimilar as important weapon for Chuikyo(Central social Insurance Medical Council) to curb healthcare cost. Further, "Biosame" pricing game will play a major role in the future for biosimilar penetration. We see that Abenomics measures and government involvement in biosimilars use would lead to the Biosimilars promotions in the coming times in Japan.

Browse our full report with Table of Contents : https://www.bharatbook.com/marketreports/japan-biosimilars-landscape-today-outlook-tomorrow/1941707